# TAC Versus TC for Adjuvant Breast Cancer

> **NCT00493870** · PHASE3 · COMPLETED · sponsor: **US Oncology Research** · enrollment: 1961 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00493870
- **Lead sponsor:** US Oncology Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05-29
- **Primary completion:** 2015-05-31
- **Final completion:** 2020-03-30
- **Target enrollment:** 1961 (ACTUAL)
- **Last updated:** 2023-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00493870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00493870, "TAC Versus TC for Adjuvant Breast Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00493870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*